Compare Quest Diagnostics Inc (DGX) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Otis Worldwide Corp — how do they compare? Quest Diagnostics Inc trades at $237.31 (market cap $26.21B), while Otis Worldwide Corp trades at $73.62 (market cap $27.80B). The key difference: Quest Diagnostics Inc and Otis Worldwide Corp are close in size by market cap, and Otis Worldwide Corp pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| DGX | OTIS | |
|---|---|---|
Market Cap | $26.21B | $27.80B |
Sector | Health | Industrials |
52-Week High | $238.50 | $93.62 |
52-Week Low | $173.49 | $69.34 |
Enterprise Value | $31.97B | $35.84B |
Dividend Yield | 1.45% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Otis Worldwide (OTIS) trades at $73.58, up 0.97% on the day, with a neutral technical signal. The company reported mixed Q2 2026 results, beating revenue estimates but missing EPS expectations and cutting full-year profit guidance due to margin pressures. Strong service segment growth, particularly in modernization, contrasts with weak new equipment demand. Analyst consensus is divided with a $92.50 price target, suggesting significant upside from current levels.
The outlook balances service-driven revenue momentum against near-term margin headwinds. Investment opportunity lies in Otis's defensive service business and global market leadership, but risks include execution on margin improvement, China exposure, and competitive pressures. Cash flow volatility and high debt levels require monitoring for sustained shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
